Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

REDWOOD CITY, Calif. & BOSTON --(BUSINESS WIRE)--Apr. 28, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025 , in New Orleans, LA . Details of the oral presentation are as follows: Title : ADI-270, an Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy, Demonstrates Robust CAR-Directed and -Independent Anti-Tumor Activity Against Hematologic and Solid Tumor Models Compared to Conventional CAR αβ T Cells Session Name : Engineered Immune Effector Cells for Solid Tumors Presenting Author: Melinda Au Date and Time : May 17, 2025 ; 11:45 a.m. – 12:00 p.m. CT About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20250428536799/en/ Adicet Bio, Inc. Investor and Media Contacts Investors: Anne Bowdidge [email protected] Janhavi Mohite Precision AQ 212-362-1200 [email protected] Media: Kerry Beth Daly [email protected] Source: Adicet Bio, Inc.

The release as fetched from its publisher. adicetbio.com ↗